Novartis expands Cosentyx label to adolescents with hidradenitis suppurativa

FDA approves Novartis Cosentyx for adolescent hidradenitis suppurativa. Discover what this decision means for biologic treatment strategies.

FDA approves Novartis Cosentyx for adolescent hidradenitis suppurativa. Discover what this decision means for biologic treatment strategies.